What Role Can Testosterone Play in Menopause Care?

Why Testosterone Declines During Menopause

Testosterone is not exclusively a male hormone. In premenopausal women, the ovaries and adrenal glands together produce roughly 300 mcg of testosterone daily, and serum total testosterone averages 20-50 ng/dL across the reproductive years. That production starts falling well before the final menstrual period. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed that total and free testosterone concentrations decline steadily from the third decade of life, with the steepest drop occurring between ages 20 and 45, independent of menopause itself.

The Surgical Menopause Problem

Bilateral oophorectomy removes both ovaries and eliminates the ovarian contribution to testosterone almost immediately. Women who undergo surgical menopause at any age experience an acute androgen deficiency that is more abrupt than the gradual decline seen in natural menopause. A 2003 study in the New England Journal of Medicine (N=75) found that surgically menopausal women who received transdermal testosterone 300 mcg/day reported significantly more satisfying sexual events per four weeks compared with placebo (mean difference 2.1 events, P<0.001), establishing a clear efficacy signal in this population.

Natural Menopause and Androgen Status

During natural menopause, estrogen falls more sharply than testosterone, so the androgen-to-estrogen ratio actually increases transiently. Still, absolute testosterone levels are lower than in younger years, and sex hormone-binding globulin (SHBG) rises with age, further reducing free (bioavailable) testosterone. Davison and colleagues (2005) documented that free testosterone index in women aged 60-69 was approximately 60% lower than in women aged 18-24, underscoring a real physiological deficit even in naturally menopausal women.

Why SHBG Matters

Free testosterone, not total testosterone, is the fraction that enters cells and binds androgen receptors. Oral estrogen raises SHBG substantially, which can reduce free testosterone even when total levels appear adequate. This interaction means women taking oral estradiol may benefit from testosterone monitoring specifically for free testosterone rather than total alone, a point the 2019 Global Consensus Position Statement on testosterone in women makes explicitly.

Testosterone and Sexual Function: The Strongest Evidence Base

The most well-replicated clinical benefit of testosterone in postmenopausal women is improvement in hypoactive sexual desire disorder. HSDD is defined as persistent, distressing low sexual desire not explained by another condition or medication. Estimates suggest HSDD affects 8-10% of women overall and up to 30% of postmenopausal women. The 2019 Global Consensus Position Statement, endorsed by 11 international societies including the International Menopause Society and the British Menopause Society, concluded that "testosterone therapy for postmenopausal women with HSDD has the best available evidence for safety and efficacy in the short to medium term."

APHRODITE Trial Results

The APHRODITE trial (N=814) enrolled naturally menopausal women not using systemic estrogen and randomized them to transdermal testosterone 300 mcg/day patch or placebo for 52 weeks. Published in the New England Journal of Medicine in 2008, the trial showed that the testosterone group experienced 2.1 more satisfying sexual events per four weeks compared with 0.7 in the placebo group (P<0.001), alongside significant improvements in desire, arousal, and orgasm scores on the Profile of Female Sexual Function scale.

The INTIMATE SM Trials

The INTIMATE SM1 and SM2 trials focused specifically on surgically menopausal women. INTIMATE SM1 (N=533) demonstrated that testosterone 300 mcg/day patch produced a 74% increase in satisfying sexual events from baseline vs. A 23% increase with placebo. Androgenic side effects (acne, unwanted hair growth) were mild and occurred in fewer than 5% of participants at the 300 mcg/day dose.

Meta-Analysis Confirmation

A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology (36 RCTs, N=8,480) ranked testosterone as the most effective intervention for HSDD in postmenopausal women among all treatments assessed, outperforming placebo on sexual function composite scores across multiple domains. The authors noted that the evidence for safety was reassuring at physiological doses over periods up to 24 months.

Bone Density: A Secondary But Meaningful Benefit

Androgen receptors are expressed on osteoblasts and osteoclasts, meaning testosterone can directly influence bone remodeling. This matters because postmenopausal osteoporosis affects approximately 10 million Americans and is responsible for 1.5 million fractures annually, according to NIH Osteoporosis and Related Bone Diseases data.

Davis Implant RCT Findings

Davis and colleagues published a placebo-controlled RCT in which postmenopausal women received subcutaneous testosterone implants (50 mg every 3 months) or placebo over 24 months. Lumbar spine bone mineral density (BMD) increased by 3.8% in the testosterone group vs. A loss of 1.2% in the placebo group (P<0.01). This effect was seen both in women using concurrent estrogen therapy and in those who were not, suggesting an independent anabolic effect on bone.

Combination with Estrogen

When testosterone is added to standard estrogen-based hormone therapy (HRT), bone protection may be additive. A 2001 study in Maturitas (N=34) found that women receiving combined estrogen-testosterone implants achieved greater gains in spinal BMD at 12 months than women on estrogen alone, with mean differences reaching statistical significance at P<0.05. Larger-scale fracture endpoint trials in women are still needed before testosterone can be recommended as a first-line osteoporosis agent, but the bone signal is consistent across multiple smaller studies.

Mood, Energy, and Quality of Life

Depression and fatigue are common complaints during the menopausal transition, and they do not always resolve with estrogen therapy alone. Testosterone receptors exist throughout the limbic system, prefrontal cortex, and hypothalamus, providing a biological rationale for mood effects.

Evidence for Mood Improvement

A randomized, double-blind crossover trial published in Menopause (N=40) found that subcutaneous testosterone implants (50 mg) significantly reduced scores on the General Health Questionnaire (GHQ-28) compared with placebo at 12 weeks. Women also reported improvements in energy, wellbeing, and sleep quality. The effect size was moderate (Cohen's d approximately 0.5), suggesting a clinically meaningful but not dramatic benefit.

Fatigue and Androgen Receptor Sensitivity

Individual variation in androgen receptor sensitivity, partly determined by the CAG repeat length polymorphism in the androgen receptor gene, may explain why some women notice dramatic mood improvements with testosterone while others do not. Research from the journal Psychoneuroendocrinology found that shorter CAG repeats, indicating higher receptor sensitivity, predicted greater mood response to androgen supplementation in women. Clinicians assessing non-responders should consider this biological variability.

Cognitive Function: Promising but Preliminary

Testosterone appears to influence verbal memory, spatial cognition, and processing speed in women. Androgen receptors are densely expressed in the hippocampus and prefrontal cortex, regions central to memory consolidation.

Neurobiological Basis

A 2014 review in Frontiers in Neuroendocrinology summarized evidence that testosterone and its metabolite estradiol (via aromatization in neural tissue) both contribute to synaptic plasticity in hippocampal networks. Women with lower free testosterone were more likely to score below age-matched norms on verbal fluency and working memory tasks in cross-sectional analyses, though causation has not been established.

Clinical Trial Data

A small RCT (N=92) published in Psychoneuroendocrinology in 2004 found that transdermal testosterone applied for 26 weeks improved verbal learning and memory scores in postmenopausal women compared with placebo, with statistical significance at P<0.05 on the Rey Auditory Verbal Learning Test. Effect sizes were modest, and the authors appropriately cautioned against drawing firm clinical conclusions without replication in larger trials. Cognitive benefit is the weakest arm of the testosterone-in-menopause evidence base, but the signal warrants ongoing study.

Cardiovascular Considerations

Cardiovascular safety is a legitimate concern with any hormone therapy. The picture with testosterone in women is more nuanced than in men, partly because the doses used are much lower and partly because some testosterone is aromatized to estradiol in peripheral tissue.

Lipid Effects

Oral methyltestosterone has been associated with reductions in HDL cholesterol, a concerning finding for cardiovascular risk. Transdermal and implant formulations, by avoiding first-pass hepatic metabolism, produce far smaller lipid changes. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=56) found no significant change in total cholesterol, LDL, or HDL after 6 months of transdermal testosterone 300 mcg/day in postmenopausal women. This is why the 2019 Global Consensus Position Statement specifically states oral methyltestosterone should not be used.

Cardiovascular Event Data

Long-term cardiovascular event data for testosterone specifically in women remain sparse compared with the estrogen literature. The available observational data are reassuring. A 2021 Australian cohort study published in The Lancet Regional Health (N=8,283) found no significant increase in rates of myocardial infarction, stroke, or venous thromboembolism in women prescribed testosterone over a median 3.4-year follow-up period, provided serum testosterone was maintained within the normal physiological female reference range.

Dosing, Formulations, and Monitoring

No testosterone product carries an FDA approval specifically for women in the United States. Compounded transdermal testosterone cream (1% testosterone) and off-label use of men's gel products at reduced doses represent the most commonly used options in clinical practice.

Recommended Dose Range

The 2019 Global Consensus Position Statement recommends targeting a serum total testosterone level within the normal premenopausal reference range (generally 10-55 ng/dL, laboratory-dependent) using the lowest effective dose. For transdermal delivery, this typically corresponds to approximately 300 mcg/day applied to the inner thigh or abdomen. Dose adjustments should be based on symptom response and measured serum levels, not on supraphysiological targets.

Monitoring Schedule

A practical monitoring framework based on the 2019 consensus and NAMS 2022 guidance includes:

• Baseline: Total testosterone, free testosterone (or free androgen index), SHBG, hematocrit, fasting lipids, liver function tests
• 6 weeks after starting: Total and free testosterone to confirm physiological range
• Every 3-6 months for the first year: Repeat testosterone levels, hematocrit, lipids, clinical assessment of androgenic side effects
• Annually thereafter: Full panel if stable on dose

Serum levels above 55-70 ng/dL (supraphysiological for women) should prompt dose reduction. Polycythemia, acne, and hirsutism are signals of excess dosing.

What to Avoid

Oral methyltestosterone raises hematocrit, lowers HDL, and carries hepatotoxicity risk due to 17-alpha alkylation. Pellet implants offer steady-state delivery but carry a risk of supraphysiological peaks and dose overcorrection that is difficult to reverse once implanted. Intramuscular testosterone ester injections (testosterone cypionate, enanthate) produce large serum peaks followed by troughs and are generally not preferred in women, though some clinicians use them at very low doses (2-5 mg weekly) in refractory cases.

Guideline Positions: What Major Organizations Say

NAMS 2022 Position Statement

The Menopause Society (formerly NAMS) published its 2022 position statement endorsing testosterone therapy for postmenopausal women with HSDD, stating: "There is sufficient evidence to support short-term use of testosterone for treating HSDD in postmenopausal women." NAMS notes the absence of FDA-approved products but supports off-label prescribing when benefits and risks are discussed and documented.

Endocrine Society Guidelines

The Endocrine Society's 2014 clinical practice guideline on androgen therapy in women took a more cautious position, recommending against testosterone therapy outside of well-defined HSDD, citing insufficient long-term safety data at that time. The 2019 Global Consensus updated this picture substantially, though the Endocrine Society has not yet issued a full revision aligning with consensus.

British Menopause Society

The British Menopause Society fully endorses the 2019 Global Consensus and has published its own best-practice guidance on testosterone for women, emphasizing physiological dosing, regular monitoring, and thorough informed consent regarding off-label status.

Who Is a Candidate for Testosterone Therapy in Menopause?

Not every menopausal woman with low libido or fatigue is an appropriate candidate. A structured assessment should be completed before initiating therapy.

Appropriate Candidates

Women who meet the following criteria are the best candidates based on available evidence:

• Confirmed diagnosis of HSDD causing personal distress
• Postmenopausal status (surgical or natural)
• Symptoms not fully explained by relationship factors, depression, or medication side effects (especially SSRIs, which are a leading cause of acquired HSDD)
• No contraindications: androgen-sensitive cancers (breast, uterine), severe acne, polycythemia, or current pregnancy

Candidates Who Need Further Evaluation

Perimenopausal women represent a gray zone. Testosterone levels fluctuate widely in perimenopause, making baseline measurement less reliable. The 2019 Global Consensus specifically limited its strongest endorsement to postmenopausal women and noted that perimenopausal data are insufficient to make a firm recommendation.

Shared Decision-Making

Given the off-label status of all current testosterone products for women in the US, shared decision-making is not optional. Clinicians should document a discussion of known benefits, known unknowns (particularly long-term breast cancer data beyond 2 years), available formulations, monitoring requirements, and the patient's treatment goals. The NAMS 2022 position statement explicitly calls for this documentation.

Breast Cancer: Addressing the Most Common Patient Concern

Breast cancer risk is the question most women ask first when testosterone therapy is raised. The available data are generally reassuring but not yet definitive for durations beyond 2-3 years.

Androgen Receptor Biology

Breast tissue expresses both estrogen receptors and androgen receptors. Androgen receptor activation in breast cells can have an anti-proliferative effect, which is the opposite of estrogen receptor activation. A 2018 review in Endocrine-Related Cancer summarized preclinical and clinical evidence suggesting that testosterone at physiological levels may be neutral or mildly protective with respect to breast tissue proliferation, though this remains under active investigation.

Observational Data in Women Using Testosterone

The 2021 Lancet Regional Health Australian cohort (N=8,283) found a breast cancer incidence rate of 5.9 per 1,000 woman-years in testosterone users compared with 7.0 per 1,000 woman-years in age-matched non-users, a non-significant difference but directionally reassuring. The authors noted confounding by indication and called for prospective trial data.

The 2019 Global Consensus concluded that available data "do not support a causal association between testosterone therapy and breast cancer," while acknowledging that evidence beyond 2 years is limited and that women with current or recent breast cancer should not receive testosterone outside of a clinical trial.